TriaGen Wealth Management LLC Buys Shares of 25,186 Medtronic PLC $MDT

20 Apr 2026, 08:04 by Doug Wharley · The Cerbat Gem

TriaGen Wealth Management LLC purchased a new stake in Medtronic PLC (NYSE:MDT – Free Report) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 25,186 shares of the medical technology company’s stock, valued at approximately $2,419,000.

A number of other institutional investors also recently modified their holdings of MDT. Brighton Jones LLC lifted its holdings in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after purchasing an additional 381 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Medtronic during the 2nd quarter valued at approximately $299,000. Main Street Financial Solutions LLC grew its holdings in shares of Medtronic by 28.9% during the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after purchasing an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC increased its position in Medtronic by 21.3% during the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock worth $1,676,000 after purchasing an additional 3,376 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on MDT shares. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, April 11th. Mizuho lowered their price target on shares of Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Stifel Nicolaus dropped their price target on Medtronic from $105.00 to $95.00 and set a “hold” rating for the company in a research note on Monday, April 6th. Needham & Company LLC reissued a “buy” rating and set a $120.00 price objective on shares of Medtronic in a report on Thursday, March 26th. Finally, Piper Sandler reduced their price objective on Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 1st. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $109.25.

Read Our Latest Stock Report on MDT

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Stock Performance

Shares of Medtronic stock opened at $86.24 on Monday. The stock has a market cap of $110.72 billion, a price-to-earnings ratio of 24.02, a P/E/G ratio of 2.24 and a beta of 0.75. Medtronic PLC has a twelve month low of $79.93 and a twelve month high of $106.33. The company’s fifty day moving average is $91.51 and its 200 day moving average is $95.71. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT – Get Free Report) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same period last year, the company earned $1.38 EPS. Medtronic’s revenue for the quarter was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s payout ratio is currently 79.11%.

About Medtronic

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.